Exicure Virtual R&D Day 2021

Virtual, January 7, 2021

Direct Link for day of event: https://event.webcasts.com/starthere.jsp?ei=1417291&tp_key=7b6789e109


Exicure’s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich’s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure’s leadership team in discussing the company’s progress in Friedreich’s Ataxia and its expanding neuroscience pipeline.

Thursday, January 7th, 2021

09:00 am to 10:30 am ET

To ask questions by Audio please dial the following number:  (US) 877-405-1224 / (Non-US) 201-389-0848

susan_tqs9q9.jpg   Susan L. Perlman, MD, is a Clinical Professor in the Department of Neurology at the David Geffen  School of Medicine at UCLA, where she is also the Director of Clinical Trials and Director, Ataxia Clinic for UCLA’s Neurogenetics program. She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreich’s Ataxia trials.
     

jennifer_ttpcnf.jpg

  Jennifer Farmer, MS is the CEO of the Friedreich’s Ataxia Research Alliance (FARA). Since joining FARA in 2006, she has led FARA’s efforts to establish clinical research infrastructure and clinical trial readiness, grown the research grant program, and led efforts to engage bio-pharmaceutical companies in drug discovery and development for Friedreich’s Ataxia.

 

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Exicure [XCUR] $167 MM MCap
Cavro­toli­mod (AST-008) in Ph2 trials for pa­tients with Merkel Cell Car­ci­no­ma and Cu­ta­neous Squa­mous Cell Car­ci­no­ma, with Ph1b da­ta pre­sent­ed at AACR 2020. XCUR-FXN in pre­clin­i­cal de­vel­op­ment for pa­tients with Frie­dreich's Ataxia, us­ing ge­net­i­cal­ly tar­get­ed SNA ther­a­pies to re­move FXN tran­scrip­tion block­age. [more in­for­ma­tion]

Event Contact

Rebecca John
Solebury Trout